Clinical Trial Update: To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating dual-target CAR-T cells for B-cell hematologic tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Hematologic Malignancies

Drugs mentioned

• Dual-target Chimeric Antigen Receptor T Cells

Snippet

Sponsor: Hebei Senlang Biotechnology Inc., Ltd. | Conditions: 19 and 22+ B Cell Hematologic Tumors, 19 and 20+ B Cell Hematologic Tumors | Phase 1 | Status: RECRUITING